# Radiotherapy With GX Regimen as Adjuvant Therapy for High-risk Patients Following Pancreatic Cancer Surgery

> **NCT07632118** · PHASE3 · RECRUITING · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 288 (estimated)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **RADIATION:** Radiotherapy + GX
- **DRUG:** GX group

## Key facts

- **NCT ID:** NCT07632118
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-05-22
- **Primary completion:** 2029-05
- **Final completion:** 2031-05
- **Target enrollment:** 288 (ESTIMATED)
- **Last updated:** 2026-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07632118

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07632118, "Radiotherapy With GX Regimen as Adjuvant Therapy for High-risk Patients Following Pancreatic Cancer Surgery". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07632118. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*